Developer docs
API playgroundTry for free, no card

Search company profiles

Aethon Therapeutics

Full company profile

uuid000282u

Namestring
Aethon Therapeutics
Legal namestring
Aethon Therapeutics, Inc.
Websiteurl
aethontx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Aethon Therapeutics is a privately held, preclinical-stage biopharmaceutical company founded in 2022 and headquartered in New York City (incorporated in Delaware), developing antibody therapeutics that selectively kill drug-resistant cancer cells. The company is built around its proprietary HapImmune™ platform, which creates synthetic neoantigens by design: when targeted covalent inhibitors (TCIs) bind their oncogenic driver proteins (e.g., KRASG12C, EGFR), the resulting drug–target peptide conjugates (haptens) are presented on tumor cell surfaces via MHC/HLA molecules, and Aethon's antibodies are engineered to recognize these drug–peptide:HLA complexes while sparing wild-type peptides. Lead named candidates include bispecific T cell engagers AETX-R114 (paired with sotorasib) and AETX-R302 (paired with divarasib), designed to recruit cytotoxic T cells to KRASG12C inhibitor-resistant cancer cells with cross-HLA coverage.

The platform is exclusively licensed from NYU Langone Health and relies on NYU's 100-billion-sequence synthetic antibody repertoire for antibody discovery. Aethon's business model is asset-light and partnership-driven: the company is pre-revenue and not yet selling products, generating near-term inflows via strategic collaborations — most notably a multi-year deal with Revolution Medicines (announced April 2024) covering RAS(ON) inhibitor–directed bispecific antibody discovery, with full preclinical reimbursement plus upfront and contingent downstream payments tied to option exercise for clinical development and commercialization. Its longer-term monetization path is one-time licensing, milestone payments, and royalties on any partnered or independently commercialized therapeutic, distributed through standard pharmaceutical channels.

Aethon was co-founded by Apple Tree Partners (ATP), which led the $30M Series A in January 2023, alongside NYU Langone Health, and is led by CEO Paul Da Silva Jardine, Ph.D. (former Pfizer CVMD research head, ex-CEO of Staten Biotechnology acquired by Novo Nordisk) with scientific founders Shohei Koide, Ph.D. and Benjamin G. Neel, M.D., Ph.D. of NYU serving as advisors and platform inventors. The company employs 11–50 people in New York, continues to recruit immunology, antibody engineering, and peptidomics scientists, and is signaling clinical readiness through peer-reviewed publications (Cancer Discovery, Nature Communications) and AACR 2025 presentations.

Short descriptiontext

Aethon Therapeutics is a preclinical-stage biotech developing the HapImmune™ platform, which engineers bispecific antibodies that selectively kill drug-resistant cancer cells by recognizing drug–peptide:HLA complexes created by targeted covalent inhibitors of oncogenic drivers such as KRASG12C.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, antibody therapeutics, bispecific T cell engagers, targeted oncology, drug-resistant cancer
Industry2 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Development and Commercialization
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing novel antibody therapeutics for cancer treatment. Revenue will be generated through potential product sales and licensing arrangements following regulatory approval.

aethontx.com
2Strategic Partnerships and Collaborations
TypeLicensing Royalties
Description

Multi-year collaboration with Revolution Medicines includes upfront payments and potential downstream payments covering future development and commercialization activities should Revolution Medicines exercise its option.

aethontx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aethon Therapeutics is a clinical-stage biopharmaceutical company that engineers novel antibody therapeutics using its proprietary HapImmune™ platform. The company combines immunotherapy with targeted covalent inhibitors (TCIs) of RAS, EGFR, and other oncogenic driver mutations to create synthetic neoantigens that bispecific T cell engagers can recognize, enabling selective killing of drug-resistant cancer cells including persister cells that survive targeted therapy.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aethon Therapeutics is a biotechnology company that has developed a unified platform approach centered on the HapImmune™ platform. The company's portfolio consists of novel anti-drug-peptide conjugate/MHC antibodies and bispecific T cell engagers, including named candidates AETX-R114 (sotorasib companion) and AETX-R302 (divarasib companion). These products are designed to work in combination with targeted covalent inhibitors of RAS, EGFR, and other oncogenic mutations to selectively kill drug-resistant cancer cells by enabling immune detection of treatment-induced neoantigens.

Product and service5 records
1HapImmune™ Platform
CategoryDrug Discovery Platform
Description

A proprietary drug discovery platform that creates antibodies to recognize drug-peptide complexes (haptens) presented by MHC molecules on tumor cells. Uses NYU Langone Health's repertoire of 100 billion synthetic antibody sequences to identify antibodies that target covalent inhibitor-generated neoantigens while avoiding wild-type peptides. The platform produces bispecific T cell engagers with one arm directed toward drug-peptide:HLA and another toward anti-CD3 and/or other T cell surface proteins.

2AETX-R114 (sotorasib companion)
CategoryBispecific T Cell Engager Therapeutic Candidate
Description

A bispecific T cell engager designed to bind drug-modified KRASG12C peptide:MHC complexes generated by sotorasib treatment, recruiting T cells to selectively kill KRASG12C inhibitor-resistant cancer cells. Designed for use in combination with sotorasib to overcome acquired resistance in KRASG12C-mutated cancers.

3AETX-R302 (divarasib companion)
CategoryBispecific T Cell Engager Therapeutic Candidate
Description

A bispecific T cell engager designed to bind drug-modified KRASG12C peptide:MHC complexes generated by divarasib treatment, enabling cross-HLA recognition and potent T-cell-mediated killing of inhibitor-resistant cancer cells. Designed for use in combination with Revolution Medicines' RAS(ON) inhibitors.

4Anti-Drug-Peptide Conjugate/MHC Antibodies
CategoryAntibody Therapeutics Pipeline
Description

A class of novel antibody therapeutics designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other oncogenic driver mutations. These antibodies mount immune attacks that selectively kill residual cancer cells including drug-resistant persister cells, addressing treatment resistance in cancer therapy.

5Bispecific T Cell Engagers (Platform Output)
CategoryBispecific T Cell Engager Therapeutic Platform
Description

Engineered antibodies produced by the HapImmune™ platform with one arm directed toward drug-peptide:HLA complexes and another toward anti-CD3 and/or other T cell surface proteins to recruit cytotoxic T cells to tumor cells. Used to mount selective immune attacks on cancer cells displaying covalent inhibitor-generated neoantigens.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-04
Description

Aethon will use its HapImmune™ platform to discover novel bispecific antibodies directed towards cancer cells hit by Revolution Medicines' RAS(ON) inhibitors. Multi-year collaboration with full preclinical work reimbursement by Revolution Medicines. Revolution Medicines has option to conduct clinical development with upfront and potential downstream payments covering future development and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-09
Description

NYU Langone Health's Perlmutter Cancer Center researchers Shohei Koide, Ph.D. and Benjamin G. Neel, M.D., Ph.D. co-founded Aethon and serve as scientific advisors. NYU Langone Health exclusively licensed pending patent applications and expertise covering the HapImmune™ platform to Aethon, participated in Series A funding, and holds equity in the company.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Revolution Medicines is Aethon's strategic partner and a leading RAS(ON) inhibitor developer. Both companies work in the RAS-driven oncology space and co-develop antibody-RAS inhibitor combinations; RevMed's clinical pipeline determines the addressable market for Aethon's companion bispecifics.

TypeDirect peer
Description

Mirati developed divarasib (G12C inhibitor) and was acquired by Bristol Myers Squibb. Aethon's AETX-R302 is designed as a divarasib companion, putting the two companies in a tightly coupled commercial and scientific relationship in KRASG12C combination therapy.

TypeBroad incumbent
Description

Amgen markets sotorasib (Lumakras), the first FDA-approved KRASG12C inhibitor and the drug that Aethon's AETX-R114 is designed to complement. Amgen's commercial trajectory and lifecycle management decisions directly shape Aethon's commercial opportunity.

TypeDirect peer
Description

Erasca is a clinical-stage precision oncology company developing RAS/MAPK pathway inhibitors. Comparable to Aethon in stage and focus on RAS-driven cancers, with overlapping interest in combination strategies to overcome resistance.

TypeDirect peer
Description

Black Diamond is a precision oncology biotech developing allosteric mutant-selective inhibitors across oncogenic drivers. Comparable in stage, focus on resistance mutations, and emphasis on master-key targeting of oncogenic proteins.

TypeEmerging player
Description

Foghorn is a clinical-stage biotech developing medicines targeting chromatin biology in cancer. While its mechanism differs, Foghorn is a similarly staged, similarly capitalized oncology platform company pursuing genetically defined patient populations.

7Theseus Pharmaceuticals
TypeEmerging player
Description

Theseus developed next-generation tyrosine kinase inhibitors designed to address resistance mutations in oncology. Comparable to Aethon in its focus on overcoming resistance to targeted therapies in cancer, although Theseus has since restructured.

TypeBroad incumbent
Description

Harpoon developed T cell engagers for solid tumors and was acquired by Merck in 2024. Directly relevant as a bispecific T cell engager peer in oncology, with shared challenges of solid-tumor immune engagement that Aethon's HapImmune candidates must solve.

TypeEmerging player
Description

Marengo is a clinical-stage precision immuno-oncology company developing T cell receptor-based therapies. Comparable to Aethon in targeting intracellular tumor antigens via innovative antibody engineering for solid-tumor oncology.

TypeBroad incumbent
Description

BioNTech is a major biopharmaceutical company with broad immunotherapy and neoantigen programs, including the immunopeptidomics/MHC-I expertise that Aethon's Executive Director Lauren Stopfer helped build. Comparable as a competitor in MHC-restricted neoantigen targeting.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aethon Therapeutics

Oncology Biopharmaceuticalsaethontx.com

Aethon Therapeutics is a preclinical-stage biotech developing the HapImmune™ platform, which engineers bispecific antibodies that selectively kill drug-resistant cancer cells by recognizing drug–peptide:HLA complexes created by targeted covalent inhibitors of oncogenic drivers such as KRASG12C.

What Aethon Therapeutics does

Aethon Therapeutics is a privately held, preclinical-stage biopharmaceutical company founded in 2022 and headquartered in New York City (incorporated in Delaware), developing antibody therapeutics that selectively kill drug-resistant cancer cells. The company is built around its proprietary HapImmune™ platform, which creates synthetic neoantigens by design: when targeted covalent inhibitors (TCIs) bind their oncogenic driver proteins (e.g., KRASG12C, EGFR), the resulting drug–target peptide conjugates (haptens) are presented on tumor cell surfaces via MHC/HLA molecules, and Aethon's antibodies are engineered to recognize these drug–peptide:HLA complexes while sparing wild-type peptides. Lead named candidates include bispecific T cell engagers AETX-R114 (paired with sotorasib) and AETX-R302 (paired with divarasib), designed to recruit cytotoxic T cells to KRASG12C inhibitor-resistant cancer cells with cross-HLA coverage.

The platform is exclusively licensed from NYU Langone Health and relies on NYU's 100-billion-sequence synthetic antibody repertoire for antibody discovery. Aethon's business model is asset-light and partnership-driven: the company is pre-revenue and not yet selling products, generating near-term inflows via strategic collaborations — most notably a multi-year deal with Revolution Medicines (announced April 2024) covering RAS(ON) inhibitor–directed bispecific antibody discovery, with full preclinical reimbursement plus upfront and contingent downstream payments tied to option exercise for clinical development and commercialization. Its longer-term monetization path is one-time licensing, milestone payments, and royalties on any partnered or independently commercialized therapeutic, distributed through standard pharmaceutical channels.

Aethon was co-founded by Apple Tree Partners (ATP), which led the $30M Series A in January 2023, alongside NYU Langone Health, and is led by CEO Paul Da Silva Jardine, Ph.D. (former Pfizer CVMD research head, ex-CEO of Staten Biotechnology acquired by Novo Nordisk) with scientific founders Shohei Koide, Ph.D. and Benjamin G. Neel, M.D., Ph.D. of NYU serving as advisors and platform inventors. The company employs 11–50 people in New York, continues to recruit immunology, antibody engineering, and peptidomics scientists, and is signaling clinical readiness through peer-reviewed publications (Cancer Discovery, Nature Communications) and AACR 2025 presentations.

Aethon Therapeutics firmographics

Firmographics
Name
Aethon Therapeutics
Legal name
Aethon Therapeutics, Inc.
Website
https://aethontx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Aethon Therapeutics is a preclinical-stage biotech developing the HapImmune™ platform, which engineers bispecific antibodies that selectively kill drug-resistant cancer cells by recognizing drug–peptide:HLA complexes created by targeted covalent inhibitors of oncogenic drivers such as KRASG12C.
Ownership category
akta.pro rank

Aethon Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Cancer immunotherapy
  • Antibody therapeutics
  • Bispecific T cell engagers
  • Targeted oncology
  • Drug-resistant cancer

Where Aethon Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aethon Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Therapeutic Development and Commercialization: Pre-revenue biopharmaceutical company developing novel antibody therapeutics for cancer treatment. Revenue will be generated through potential product sales and licensing arrangements following regulatory approval.
  2. Strategic Partnerships and Collaborations: Multi-year collaboration with Revolution Medicines includes upfront payments and potential downstream payments covering future development and commercialization activities should Revolution Medicines exercise its option.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Aethon Therapeutics product offering

Product offering

Core offering

Aethon Therapeutics is a clinical-stage biopharmaceutical company that engineers novel antibody therapeutics using its proprietary HapImmune™ platform. The company combines immunotherapy with targeted covalent inhibitors (TCIs) of RAS, EGFR, and other oncogenic driver mutations to create synthetic neoantigens that bispecific T cell engagers can recognize, enabling selective killing of drug-resistant cancer cells including persister cells that survive targeted therapy.

Product overview

Aethon Therapeutics is a biotechnology company that has developed a unified platform approach centered on the HapImmune™ platform. The company's portfolio consists of novel anti-drug-peptide conjugate/MHC antibodies and bispecific T cell engagers, including named candidates AETX-R114 (sotorasib companion) and AETX-R302 (divarasib companion). These products are designed to work in combination with targeted covalent inhibitors of RAS, EGFR, and other oncogenic mutations to selectively kill drug-resistant cancer cells by enabling immune detection of treatment-induced neoantigens.

Differentiator

Problem solved

Functional benefit

Products and services

  • HapImmune™ Platform A proprietary drug discovery platform that creates antibodies to recognize drug-peptide complexes (haptens) presented by MHC molecules on tumor cells. Uses NYU Langone Health's repertoire of 100 billion synthetic antibody sequences to identify antibodies that target covalent inhibitor-generated neoantigens while avoiding wild-type peptides. The platform produces bispecific T cell engagers with one arm directed toward drug-peptide:HLA and another toward anti-CD3 and/or other T cell surface proteins.
  • AETX-R114 (sotorasib companion) A bispecific T cell engager designed to bind drug-modified KRASG12C peptide:MHC complexes generated by sotorasib treatment, recruiting T cells to selectively kill KRASG12C inhibitor-resistant cancer cells. Designed for use in combination with sotorasib to overcome acquired resistance in KRASG12C-mutated cancers.
  • AETX-R302 (divarasib companion) A bispecific T cell engager designed to bind drug-modified KRASG12C peptide:MHC complexes generated by divarasib treatment, enabling cross-HLA recognition and potent T-cell-mediated killing of inhibitor-resistant cancer cells. Designed for use in combination with Revolution Medicines' RAS(ON) inhibitors.
  • Anti-Drug-Peptide Conjugate/MHC Antibodies A class of novel antibody therapeutics designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other oncogenic driver mutations. These antibodies mount immune attacks that selectively kill residual cancer cells including drug-resistant persister cells, addressing treatment resistance in cancer therapy.
  • Bispecific T Cell Engagers (Platform Output) Engineered antibodies produced by the HapImmune™ platform with one arm directed toward drug-peptide:HLA complexes and another toward anti-CD3 and/or other T cell surface proteins to recruit cytotoxic T cells to tumor cells. Used to mount selective immune attacks on cancer cells displaying covalent inhibitor-generated neoantigens.

Companies that use Aethon Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Aethon Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aethon Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Revolution MedicinescoreStrategic or Co-development Partner · 4 April 2024Aethon will use its HapImmune™ platform to discover novel bispecific antibodies directed towards cancer cells hit by Revolution Medicines' RAS(ON) inhibitors. Multi-year collaboration with full preclinical work reimbursement by Revolution Medicines. Revolution Medicines has option to conduct clinical development with upfront and potential downstream payments covering future development and commercialization.
  • NYU Langone HealthcoreStrategic or Co-development Partner · 9 January 2023NYU Langone Health's Perlmutter Cancer Center researchers Shohei Koide, Ph.D. and Benjamin G. Neel, M.D., Ph.D. co-founded Aethon and serve as scientific advisors. NYU Langone Health exclusively licensed pending patent applications and expertise covering the HapImmune™ platform to Aethon, participated in Series A funding, and holds equity in the company.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Aethon Therapeutics competitors and assessment

Company assessment

Direct peers

  • Revolution Medicines: Revolution Medicines is Aethon's strategic partner and a leading RAS(ON) inhibitor developer. Both companies work in the RAS-driven oncology space and co-develop antibody-RAS inhibitor combinations; RevMed's clinical pipeline determines the addressable market for Aethon's companion bispecifics.
  • Mirati Therapeutics: Mirati developed divarasib (G12C inhibitor) and was acquired by Bristol Myers Squibb. Aethon's AETX-R302 is designed as a divarasib companion, putting the two companies in a tightly coupled commercial and scientific relationship in KRASG12C combination therapy.
  • Erasca: Erasca is a clinical-stage precision oncology company developing RAS/MAPK pathway inhibitors. Comparable to Aethon in stage and focus on RAS-driven cancers, with overlapping interest in combination strategies to overcome resistance.
  • Black Diamond Therapeutics: Black Diamond is a precision oncology biotech developing allosteric mutant-selective inhibitors across oncogenic drivers. Comparable in stage, focus on resistance mutations, and emphasis on master-key targeting of oncogenic proteins.

Broad incumbents

  • Amgen: Amgen markets sotorasib (Lumakras), the first FDA-approved KRASG12C inhibitor and the drug that Aethon's AETX-R114 is designed to complement. Amgen's commercial trajectory and lifecycle management decisions directly shape Aethon's commercial opportunity.
  • Harpoon Therapeutics: Harpoon developed T cell engagers for solid tumors and was acquired by Merck in 2024. Directly relevant as a bispecific T cell engager peer in oncology, with shared challenges of solid-tumor immune engagement that Aethon's HapImmune candidates must solve.
  • BioNTech: BioNTech is a major biopharmaceutical company with broad immunotherapy and neoantigen programs, including the immunopeptidomics/MHC-I expertise that Aethon's Executive Director Lauren Stopfer helped build. Comparable as a competitor in MHC-restricted neoantigen targeting.

Emerging players

  • Foghorn Therapeutics: Foghorn is a clinical-stage biotech developing medicines targeting chromatin biology in cancer. While its mechanism differs, Foghorn is a similarly staged, similarly capitalized oncology platform company pursuing genetically defined patient populations.
  • Theseus Pharmaceuticals: Theseus developed next-generation tyrosine kinase inhibitors designed to address resistance mutations in oncology. Comparable to Aethon in its focus on overcoming resistance to targeted therapies in cancer, although Theseus has since restructured.
  • Marengo Therapeutics: Marengo is a clinical-stage precision immuno-oncology company developing T cell receptor-based therapies. Comparable to Aethon in targeting intracellular tumor antigens via innovative antibody engineering for solid-tumor oncology.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Aethon Therapeutics social profiles

Digital presence

Aethon Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aethon Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Aethon Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aethon Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aethon Therapeutics

What does Aethon Therapeutics do?

Aethon Therapeutics is a clinical-stage biopharmaceutical company that engineers novel antibody therapeutics using its proprietary HapImmune™ platform. The company combines immunotherapy with targeted covalent inhibitors (TCIs) of RAS, EGFR, and other oncogenic driver mutations to create synthetic neoantigens that bispecific T cell engagers can recognize, enabling selective killing of drug-resistant cancer cells including persister cells that survive targeted therapy.

Is Aethon Therapeutics a public or private company?

Aethon Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aethon Therapeutics founded?

Aethon Therapeutics was founded in 2022. It employs 11 to 50 people.

Where is Aethon Therapeutics based?

Aethon Therapeutics is headquartered in New York, United States, in the North America region.

How does Aethon Therapeutics make money?

Two revenue lines are on record. Therapeutic Development and Commercialization is the primary driver. The others are strategic Partnerships and Collaborations.

Who are Aethon Therapeutics's main competitors?

Direct peers on record are Revolution Medicines, Mirati Therapeutics, Erasca and Black Diamond Therapeutics. Broad incumbents are Amgen, Harpoon Therapeutics and BioNTech. Emerging players are Foghorn Therapeutics, Theseus Pharmaceuticals and Marengo Therapeutics.

Does Aethon Therapeutics have an API?

No public API is recorded for Aethon Therapeutics.

What industry is Aethon Therapeutics in?

Aethon Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer CellsAethon Therapeutics launched in New York City to develop novel antibodies that eliminate drug resistance in cancer treatment by combining immunotherapy with targeted therapy. The company secured $30 million in Series A financing, with $25 million from Apple Tree Partners (ATP), which co-founded the company alongside researchers from NYU Langone Health's Perlmutter Cancer Center. The company's HapImmune™ platform, described in a publication in Cancer Discovery, uses customized antibodies to target and kill persistent cancer cells that have developed resistance to drugs such as KRAS and EGFR inhibitors.AethontxATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells – Aethon TherapeuticsApple Tree Partners (ATP) and NYU Langone Health launched Aethon Therapeutics to develop novel antibodies that eliminate drug-resistant cancer cells. The new company secured $30 million in Series A funding, with ATP providing $25 million and holding equity alongside NYU Langone Health. Aethon will utilize the HapImmune platform, licensed exclusively from NYU Langone Health, to create targeted therapies for oncogenic mutations such as RAS and EGFR.BioSpaceATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer CellsApple Tree Partners and NYU Langone Health co-founded Aethon Therapeutics to develop novel antibodies designed to eliminate drug-resistant cancer cells. The new company secured $30 million in Series A funding, with $25 million provided by Apple Tree Partners, and will utilize the HapImmune™ platform to target oncogenic mutations.